The Spanish National Cancer Research Centre (CNIO) has announced a major breakthrough in the treatment of pancreatic cancer. The team led by Professor Mariano Barbacid achieved what had been considered impossible for decades: completely eliminating pancreatic tumors in preclinical tests conducted on mice.
What is the essence of the breakthrough?
Pancreatic cancer (adenocarcinoma) is one of the most aggressive forms of cancer. It acts as an “intelligent” adversary, masterfully finding workarounds: block one door, and it will knock out three windows. This ability is why the mortality rate remains frighteningly high. However, Barbacid’s team decided not just to “close a door,” but to collapse the entire structure at once by employing a “triple-hit” strategy.
The “Triple-Hit” Formula
The key to the new treatment’s success lies in a combination of innovative drugs that strike the tumor simultaneously, giving it no chance to adapt. The researchers realized that finding a single “magic bullet” against pancreatic cancer was impossible due to its cunning nature. Therefore, they created the “triple-hit” method, utilizing three components, some of which are true high-tech developments:
- KRAS (experimental inhibitor Darovasertib) – This is the cancer’s “engine.” For decades, this protein was considered invulnerable, but modern technology allowed the creation of a molecule that was finally able to “switch it off.”
- EGFR (Afatinib drug) – This is the “emergency exit.” When the primary pathway (KRAS) is blocked, the tumor attempts to switch to EGFR. This drug intercepts the cells’ “escape attempt.”
- STAT3 (SD36 protein degrader) – This is the tumor’s “bodyguard.” Here, the revolutionary PROTAC technology is used: the SD36 molecule doesn’t just suppress the protein; it “tags” it as garbage, forcing the body to completely destroy it.
The study conducted by Professor Barbacid’s group, published in PNAS, presents statistics that oncologists might describe as a “miracle confirmed by facts”:
- 100% Regression: Tumors in mice did not merely shrink—they completely disappeared.
- “Clean Slate” Effect: The disease did not return for more than 200 days (a significant period for a rodent). No relapses were observed.
- Safety: Despite the potency of the “cocktail,” the subjects’ bodies tolerated the therapy without critical adverse effects.
Despite the convincing data, Professor Barbacid speaks cautiously, emphasizing that the team is still in the preclinical stage. Moving from mouse models to human trials is not just a change in scale; it requires complex adaptation of dosages and toxicity profiles. While the team is not promising a cure tomorrow, they have provided something far more significant—proof that this cancer is curable in principle.
